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Pyridoacridines in the 21st Century 
 
 John A. Joule [b]  and Mercedes Álvarez* [a] 
 
Abstract: This minireview summarizes the work developed 
during this Century with compounds containing the pyridoacridine 
scaffold in its different isomeric forms. The isolation of natural 
products, syntheses, bioactivities, chelation capacity, and other 
properties of compounds containing this framework are discussed. 
For reasons of length, only compounds containing a maximum of 
seven condensed rings have been considered, with a few exceptions. 
Introduction   
Interest in ‘pyridoacridines’, i.e. tetracyclic systems in which a  
pyridine  ring  is  fused  to  an  acridine – there  are  fifteen isomers 
– began with the isolation and structure determinations of 
marine alkaloids, many biologically active, based on some of 
these isomers.[1]  We earlier summarised synthetic routes to 
pyridoacridines.[2] More recently, the following relevant 
aspects have been considered: ‘ortho-Directed metallation of 
-deficient heterocycles in connection with palladium-
catalyzed biaryl cross-coupling – synthesis of marine alkaloids 
of the pyridoacridine series’,[3] ‘Marine pyridoacridine alkaloids 
and synthetic analogues as antitumor agents’,[4] ‘Biological 
activities of pyridoacridines’[5] ‘A mini review on 
pyridoacridines: prospective lead compounds in medicinal 
chemistry’,[6] ‘Alkaloids from marine invertebrates as important 
leads for anticancer drugs discovery and development’,[7] 
‘Marine pyridoacridine alkaloids: biosynthesis and biological 
activities’,[8] and ‘New perspectives in the chemistry of marine 
pyridoacridine alkaloids’.[9] 
 
In this review we consider all of the fifteen isomers, including 
natural product chemistry and synthesis reported in the 21st 
Century. Each isomer is named as a ‘pyrido[A,B-yz]acridine’ 
to emphasise the isomeric relationship, but where this name 
is not the systematic name, the Chemical Abstracts name is 
given in {brackets}. We do not cover in detail spectroscopic, 
other physico-chemical, or bioactive aspects. We have 
included extended examples but only up to hexacyclic 
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1.   Pyrido[4,3,2-kl]acridine     
 
Perhaps the obvious starting material for the construction of 
pyrido-acridines is a suitably functionalised acridine. For 
example, ethacridine 1 was transformed into chloro 
compound 2 and this into the 2,2-dimethoxyethanamine 3, 
acid-catalysed closure of which produced (Scheme 1) a 
pyrido[4,3,2-kl]acridine 4.[10]   
 
Electrophilic substitution of 3 with 4-nitrophenyldiazonium 
fluoroborate allows later introduction of an amine function by 
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reduction and thence by condensation with 1,10-
phenanthroline-5,6-dione, formation of octacyclic analogue 5 




Scheme 1. Synthesis of a pyrido[4,3,2-kl]acridine from an acridine 1; 
synthesis of 5, analogue of eilatin.[10] 
 
Alkylpyrido[4,3,2-kl]acridines 7 were prepared [11,12] using the 
previously described synthetic procedure.[13] The synthesis 
starts with a cycloaddition of dimethylaminoprop-2-yne (or 5-
chloropent-1-yne) to 9-azidoacridine to give a regioisomeric 
mixture of triazolylacridines 6a and 6b (or 6c and 6d) (Scheme 
2). The disadvantage of the cycloaddition method is that 
chromatographic separation of the mixture of isomeric 
triazoles is always required and the yield of the most hindered 
triazole is the lower. Thermolysis of 6a and 6b occurs with 
elimination of nitrogen to generate a reactive biradical or 
carbene species which cyclizes giving the pyridoacridines 7a 
and 7b. Different behavior of the regioisomeric acridines 6c 
and 6d was found in the thermolysis. Isomer 6c cyclized to 3-
(3-chloropropyl)pyridoacridine 7c. The direct thermolysis of 3-
chloropropyl derivative 6d gave the water-soluble pentacyclic 
salt 8 via intramolecular cyclization of assumed 
chloropropylpyridoacridine intermediate 7d. 
 
Scheme 2. Synthesis of 7H-pyrido[4,3,2-kl]acridines 7 and the 
acridinium salt 8.[11,12] 
A better yield of the acridine 7b was achieved using an 
alternative procedure (Scheme 3) based on the reaction of 9-
azidoacridine with chloroacetonyltriphenylphosphorane ylide 
to give the chloromethyltriazolylacridine 6e. Attempts at 
thermolysis of the chloromethyl derivative 6e were 
unsuccessful. However, acridine 6e reacted smoothly with 
dimethylamine at 30-40 ºC to give pyridoacridine 7b.[14]  
 
Scheme 3. Synthesis of triazoloacridine 6e and alternative synthesis 
of 7b.[11,14] 
 In vitro biological evaluation of polycyclic acridines, the core 
heterocyclic framework of which is structurally related to 
bioactive marine natural products was performed.[29]  
Potentially the most interesting compound is the 
indolizino[7,6,5-kl]acridinium salt 8 (see Scheme 2).  The 
intercalating ability at G-C DNA and inhibition of topo II were 
the most significant results. The water-soluble compound 8 is 
a potent inducer of apoptosis in lung and breast cancer cell 
lines.  
 
Scheme 4. Preparation of derivatives of pyridoacridine 9.[15] 
 
The reactivity of 4-methoxy-pyrido[4,3,2-kl]acridines as 
electron-rich aromatics allowed  access to a series of 6-
functionalized derivatives (Scheme 4).[15] The starting 
compound, 9-chloro-4-methoxypyrido[4,3,2-kl]acridine 9, was 
obtained as described in previous work.[16] As shown in 
Scheme 4, H-D exchange in trifluoroacetic acid-d was 
performed at room temperature to give deuteration 
 






regioselectively at position 6, compound 10. Vilsmeier–Haack 
reaction using phosphoryl chloride with DMF proceeded 
smoothly to give the compound 11 with incorporation of one 
formyl group at the same position. Functional group 
interchange of the formyl group in 11 by reduction or reaction 
with methoxyamine afforded the derivatives 12 and 13, 
respectively. N-Alkylation of 9 using methyl iodide and sodium 
hydride in DMF gave compound 14. Oxidation of 9 with ceric 
ammonium nitrate (CAN) produced the pyridoacridone 15. 
 
The reactivity of compound 15 with nucleophiles is 
characteristic of an iminoquinone, thus with an excess of 
primary amines and spontaneous oxidation of the initial 
Michael adduct, the enones 16 were produced (Scheme 5). 
Weaker nucleophiles such as aniline required Lewis acid 
catalysis to give, after one day, compound 17. Coupling of 
compounds 15 and 16f gave the dimeric structure 18; this 
compound may act as a DNA-intercalator. Addition of -
mercaptoethanol at room temperature followed by 
spontaneous oxidation afforded compound 19. In contrast to 
these conjugate additions, methoxyamine reacts to give the 




Scheme 5. Preparation of derivatives of pyridoacridone 15.[15, 17] 
 
A series of glyco-conjugates derived from 
chloropyridoacridine 11 (Scheme 6) were prepared to test as 
potential antitumor agents.[17] The glycoconjugates 22 were 
obtained by chemoselective reaction of the aldehyde group in 
11 with the aminooxy sugars 23 forming oximes 21. Oxidation 
with CAN then led to the iminoquinones 22. 
 
The compounds 16 and 22 were tested against HT-29 cancer 
cells. The glycoconjugates are not cytotoxic compared to the 






Scheme 6. Synthesis of glyco-conjugates 22a-d.[17] 
 
Studies on the biosynthesis of the fungal alkaloid necatorone 
using fluorine-labeled 3-(2-carboxyphenylamino)-L-tyrosine in 
feeding experiments demonstrated no incorporation of this 
amino acid.[18] However, the synthesis of the 
dideoxynecatorone derivative 29 using the protected 




Scheme 7. Synthesis of dideoxynecatorone derivative 29.[18] 
 
The amino acid 26 obtained by a copper(II) acetate mediated 
coupling reaction between 24 and the iodonium salt 25 
underwent a cyclization in Friedel–Crafts conditions to give 27 
and following basic conditions and air oxidation gave the 
pyridoacridine 28. Oxidation of 28 with CAN afforded the 
natural product analogue 29. 
 
Two alternative synthetic routes were developed by the same 
group for the synthesis of acridinium salts 31 and 33 (Scheme 
8).[19] A double N-alkylation of the quinolinoacridine 30 
afforded the salt 31. The second route is based in the reaction 
of N-methyl-2-methylquinolinium methyl sulfates 32 in 
ethanolic piperidine to give the salts 33. 











Scheme 8. Synthesis of acridinium salts 31 and 33.[19 
 
The proposed mechanism for the formation of salts 33 is 
based on a betaine formation by reaction between the 2-
methylquinolinium salt and piperidine base (Scheme 9). 
Subsequent addition of the betaine to a second equivalent of 
the starting quinolinium salt would give the dihydroquinoline 
intermediate I-1 which, by an electrocyclic ring opening would 
proceed to the imine intermediate I-2 from which, after 
electrocyclic ring closure ( I-3) and oxidation, compound 33 




Scheme 9. Proposed mechanism for the formation of salts 33.[19] 
 
Compounds 33 (R = Me, F) are among the most potent 
telomerase inhibitors yet disclosed, with IC50 values < 0.5 M. 
 
Although of comparable potency as telomerase inhibitors, 
compound 33 (R = Me) is 30-fold more growth inhibitory than 
33 (R = H) in the NCI 60 cell panel. The same group described 
the recognition and stabilization of the pentacyclic 
methylacridinium cation RHPS4 (Fig. 1) with d(TTAGGGT)4 







Figure 1. Structure of RHPS4.[20]  
 
Using similar chemistry, the amine 35, obtained by N-
methylation and reduction of the nitroacridine 34, gave the 
acridinium salts 36 in two steps – amine acylation of 35 and 




Scheme 10. Synthesis of acridinium salts 36.[21] 
 
The introduction of bulky saturated (3-acetoxy)propyl or (E)-3-
(morpholin-4-yl)-3-oxopropenyl substituents in the 3-, 6-, or 
10-positions of the pentacyclic nucleus was tested with the 
aim of enhancing the affinity to G-quadruplex structures.[22,23]  
Suzuki–Miyaura and Heck reactions were used for the 
synthesis of the functionalized pentacyclic acridines 38 and 39 
(Scheme 11). Alkylboranes, prepared by interaction of 9-
borabicyclo[3,3,1]nonane (9-BBN) and allyl acetate, or N-
acryloylmorpholine, were used for two successive 
cross_coupling reactions starting originally from 
quinolinoacridine 37 to give compounds 38 and 39.  
Quaternization of 38 and 39 afforded the acridinium salts 40. 
 








Scheme 11. Synthesis of substituted pentacyclic acridines 38 and 39 
and acridinium iodides 40.[22-24] 
 
Extensive studies of compound stability and metabolic 
stability of pentacyclic acridinium salts in the presence of 
cytochrome P450 enzymes, as well as intracellular drug 





Scheme 12. Synthesis of pentacyclic core of RHPS4 by an 
anionic ring_closing cascade.[26 
Quantification of relative quadruplex and duplex binding 
affinity constants places some of these ligands among the 
most selective quadruplex DNA interactive agents reported to 
date.[24,25] 
 
A convergent synthesis of the telomerase inhibitor RHPS4 
(see Fig. 1) was described by construction of the pentacyclic 
framework via an anionic ring-closing cascade in which two 
new rings are formed (Scheme 12).[26] The key intermediate 
aminonitrile 43 was obtained by nucleophilic aromatic 
substitution of the fluorine situated ortho to the cyano group in 
42 by the potassium salt of 41 followed by in situ quenching of 
the resulting diarylamine anion with methyl iodide. Treatment 
of 43 with tert-butyllithium results in double cyclization by 
exchange of bromine by lithium ( I-1), addition of the 
resulting organolithium to the cyano group ( I-2) and final 
nucleophilic substitution of fluorine by the generated imine 
anion to give 44.   
 
A benzo[b]acridine 46, obtained by an intramolecular [4+2] 
cycloaddition reaction of a ketenimine 45, was the synthetic 
intermediate for the preparation of acridine 47 (Scheme 13). 
Reduction of the nitro group of 46 gave an amine which, by 
means of an intramolecular amination of the pyridine ring, 





Scheme 13. Synthesis of hexacyclic system 47 via [4+2] 
cycloaddition.[27] 
 
2.  7H-Pyrido[3,4,5-kl]acridine    
 
Although no natural products incorporating this skeleton have 
been reported, structure 53 was prepared as an analogue of 
S-(+)-dinapsoline,[28] which has anti-Parkinson activity with 
significant metabolic and pharmacological advantages over 
other D1 agonists. 






The synthesis of 53 (Scheme 14) started with a nucleophilic 
aromatic substitution of the para-nitro-activated quinolinyl 
bromide 49 with a Boc-protected arylamine 48 giving 50. 
Following displacement of the nitro group with fluoride ( 51), 
a radical induced cyclisation provided a tetracycle, from which 
the diol and the amine protections were removed leaving 52.  
Reduction of 52 with sodium cyanoborohydride produced the 




Scheme 14. Structure of dinapsoline and synthesis of an analogue 
48.[29] 
3.  Pyrido[2,3,4-kl]acridine 
 
This pyridoacridine isomer is by far the most frequently 
encountered in the naturally occurring marine alkaloids. For 
this reason we have arbitrarily divided the coverage into 
sections based on the number of rings present. This leads to 
some overlap in that the pyrido[2,3,4-kl]acridine  skeleton 
occurs in compounds with more than one ring size by virtue of 
having other rings, benzene or pyridine, fused to it. 
3.1. Tetracyclic systems 
Pyridoacridine alkaloids isodiplamine, cystodytin K and 
lissoclinidine were isolated from the New Zealand ascidian 
Lissoclinum notti (Fig. 2).[30] Their biological activities, 




Figure 2. Structures of isodiplamine, cystodytin K and 
lissoclinidine.[30] 
The synthesis of some marine alkaloids, with tetracyclic 
skeletons, was developed using, as starting material, the 
substituted quinolone 54.[31] Transformation of amino into 
azide and thermal cyclization afforded the tetracyclic acridone 
55. Reduction of 55 to acridine 56 was achieved by 
transformation into the chloroacridine and then catalytic 





Scheme 15. Synthesis of pyridoacridine 56.[31] 
 
A biomimetic synthesis of styelsamine B was described[32] by 
a reaction between kynuramine dihydrobromide 57 and N-
acetyl dopamine (Scheme 16).  A cascade process produced 
a fast entry to styelsamine B. This compound was oxidised to 
cystodytin J using silver oxide in methanol. The authors point 
out that this is a formal total synthesis of diplamine because 





Scheme 16. Synthesis of styelsamine B[32] and cystodytin J.[33] 
 
The procedure described previously[31] for the synthesis of the 
alkaloids styelsamine B and cystodytin J was followed exactly 
for the preparation of analogues in which only the N-acyl 
group was varied.[34]  
 
A total synthesis of styelsamine C and the formal synthesis of 
norsegoline utilized as the key step a biaryl cross-coupling 
reaction.[35,36] Suzuki reaction between 4-bromoquinoline 58 
and phenylboronic acid gave the 4-phenylquinoline 59 in 
excellent yield (Scheme 17). Transformation of 59 into the 
aldehyde 60 was accomplished in two steps, based on the 
formation of an enamine by reaction of 59 with 
dimethylformamide dimethyl acetal (DMFDMA) (cf. Scheme 






18) followed by oxidative cleavage. The intramolecular nitrene 
insertion reaction
 
of 60 using triethyl phosphite gave the 
tetracyclic compound and final demethylation furnished 
styelsamine C. Oxidation of aldehyde 60 to carboxylic acid 
followed by methyl ester formation gave the nitro ester 61. The 
synthesis of norsegoline from 61 was previously described by 




Scheme 17. Total synthesis of styelsamine C and formal synthesis of 
norsegoline.[36] 
 
The functionalization of a pyridine- or quinoline-2- or 4-methyl 
group using dimethylformamide diethyl (or dimethyl) acetal 
(DMFDEA or DMFDMA) has been employed several times in 
pyridoacridine chemistry, Scheme 18 illustrates the 
mechanism using 2-methylpyridine. Briefly, dissociation of the 
reagent provides an alkoxide that deprotonates the methyl 
group forming a carbanion I-2 that reacts with the electrophilic 
iminium ion I-1. Final loss of ethanol from I-3 gives an enamine 
62 – the reaction equivalent of a 2-pyridinyl-acetaldehyde or, 





Scheme 18. Mechanism of action of DMFDEA with a 2- (or 
4-)methylpyridine. 
 
Studies of oxotetrahydroquinoline oximes 63 under conditions 
typical of Beckmann reaction provided a different entry for the 




Scheme 19. The use of typical Beckmann reaction conditions for 
synthesis of dihydro-pyrido[2,3,4-kl]acridines 64.[38] 
 
Intramolecular cyclization of 1-(N-acylamino)acridones 65 
forming pyridoacridones 66 was achieved in basic 
conditions.[39] Only secondary amides 65 (R = H) containing 
an activating substituent (X = CN, CO2Et) in the acyl group 
cyclize with potassium hydroxide in DMF to pyridoacridones 
66 (X = CN, CO2Et). However, tertiary amides 65 (R = alkyl) 
underwent cyclization in the same conditions even without an 
activating substituent in the acyl group (Scheme 20).  
 
 
Scheme 20. Cyclization of N-acylaminoacridones 66.[39] 
 
Treatment of aminoacridone 67 with phosphorus 
pentachloride in benzene and then with a malonic acid 
derivative, in the presence of a base, directly gave 
pyrido[2,3,4-kl]acridine derivatives 68 and 69. With ethyl 
cyanoacetate as active compound acridine 68 (X = CN) and 
acridin-2-one 69 (X = CN) were obtained in a ratio ~3 : 1 
(Scheme 21).[40] In the case of ethyl malonate, the same 
conditions yielded a mixture of  68 and 69 (X = CO2Et)  in 
approximately the same ratio.  With malononitrile as reactant, 
a cyclization onto the cyano group gave a product that was 




Scheme 21. Synthesis of pyrido[2,3,4-kl]acridines 68-70 from 1-
aminoacridone 67.[40] 
 
9-Chloro-1-nitroacridines 71 containing substituents in the 
nitro-benzene ring react with malononitrile in DMSO in the 
presence of potassium hydroxide yielding 9-dicyanomethyli-
denes 72 (Scheme 22).[40] Subsequent reduction of the nitro 






group was accompanied by cyclization to 4- or 6-methoxy-
substituted 1-cyano-2-iminopyrido[2,3,4-kl]acridines 73, 





Scheme 22. Synthesis of 1-cyano-2-iminopyrido[2,3,4-kl]acridines 73 
from the acridines 71.[40] 
 
The key steps in the assembly of the amino-quinone-imine 76 
are the palladium-catalysed Sonogashira cross-coupling of 
triflate 74 with trimethylsilylacetylene (TMSA) giving 75 
(Scheme 23). Later formation of the new pyridine ring in 76 
was afforded in one pot and four steps by silyl group removal, 
incorporation of a diformyl protected amino group (cf. similar 
use of sodium diformylamide and discussion of mechanism in 
Schemes 32 and 33), oxidation and cyclization with 
concomitant amino group deprotection.[41] 
 
 
Scheme 23. Synthesis of 4-amino-6H-pyrido[2,3,4-kl]acridin-6-one 
76.[41] 
 
An alternative route (Scheme 24)[42] to a tetracyclic quinone-
imine system 78 also started with a palladium-catalysed 
coupling, to generate the 4-(2-aminophenyl)quinoline 77. 
  
 
Scheme 24. Synthesis of the pyridoacridone 78.[42] 
Amide hydrolysis then oxidation to the quinone (not isolated) 
level led directly to the tetracycle 78.  
 
The synthesis and biological evaluation of a series of 
pyrido[2,3,4-kl]acridin-6-ones were developed looking for 
novel therapeutics to treat tuberculosis infections. Interesting 
compounds were 82 and 83 (Scheme 26), which were found 
to inhibit the growth of Mycobacterium tuberculosis at 
micromolar concentration, but were not cytotoxic towards 
Vero and P388 cells.[43] The common synthetic intermediate 
for all the series is the dihydroacridine-1,4-dione 81. Oxidative 
coupling of the benzoquinone 79 with 2-aminoacetophenone 
and subsequent acid-catalyzed cyclisation led to 
acridinequinone 80. The last ring of the pyridoacridone 81 was 
introduced by a one-pot annulation using paraformaldehyde 
and ammonium chloride in glacial acetic acid (Scheme 25). 
 
 
Scheme 25. Synthesis of pyrido[2,3,4-kl]acridone 81.[43] 
 
The propensity of the tolylthio group in 81 to be substituted by 
nucleophiles was used for the preparation of active 
compounds 82 and 83 (Scheme 26).  Amide 82 was prepared 
by direct reaction of 81 with N-(2-aminoethyl)pyrazine-2-
carboxamide in basic conditions. Using the same reaction 
conditions with the aminoethyl tert-butylcarbonate as 
nucleophile and subsequent removal of the protecting group, 




Scheme 26. Syntheses of pyrido[2,3,4-kl]acridones 82, 83, 85, and 
86.[43] 
 
The primary amine of 84 was reacted with tosyl chloride or 
phenylisothiocyanate to give derivatives 85 and 86, 






respectively. Finally, using ethanolamine as reagent with 81 
followed by ester formation with pyrazine carboxylic acid, 
using bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) 
as coupling agent, product 83 was obtained. 
 
3.2 Pentacyclic systems 
 
3.2.1 Natural product isolations 
 
Bioactive pyridoacridines have been isolated from four phyla 
(Porifera, Chordata-Subphylum Tunicata, Mollusca and 
Cnidaria) leading to the suggestion that they are actually 
produced by associated symbionts. Now, a study of the 
locality of a typical pyridoacridine alkaloid, dercitamide (= 
kuanoniamine C) in bacteria-free sponge cells in the marine 
sponge Oceanapia sagitaria (Sollas), strongly suggests that 
the alkaloids are probably not produced by intracellular 
symbiotic organisms. The study concludes that the 
localisation of dercitamide in significant concentrations in 
specific cells throughout the sponge means that it has 
important biological and ecological functions, such as 
chemical defence against predators and possibly against 
pathogens.[44] 
A study of the temporal variation in the production of 
shermilamine B and kuanoniamine D (Fig. 3) by the purple 
morph of the ascidian Cystodytes sp. showed there to be no 




Figure 3. Structures of some kuanoniamines and some 
shermilamines. 
 
Kuanoniamines A and C (Fig. 3), isolated from the marine 
sponge Oceanapia sagittaria (Sollas) collected from the Gulf 
of Thailand, were evaluated for their cytotoxic effect against 
five human tumour cell lines and one human non-tumour cell 
line. Kuanoniamine A proved to be a potent growth inhibitor of 
all the human tumor cell lines as well as the nontumour cell 
line. Though kuanoniamine C was found to be much less 
potent than kuanoniamine A, it was found to possess a high 
selectivity toward the estrogen dependent breast cancer cell 
line.[46] Kuanoniamine E (R = i-Pr) and kuanoniamine F (R = 
CH(Me)Et) (Fig. 3) were isolated from a Singaporean ascidian 
along with other pyridoacridines, including ascididemine ( Fig. 
4) and the ‘ring-opened’ variant 87 drawn to suggest its 
structural relationship to other pyridoacridine alkaloids.[47] The 
Australian ascidian Polysyncraton echinatum contains 12-
deoxyascididemine, along with ascididemine and the 
heptacyclic eilatin.  
 
Figure 4. Structures of ascididemine, eilatin and related 
compounds.[47] 
 
From a Xestospongia sp. collected from the Philippines and 
Palau, deoxyamphimedine was obtained,[48] along with 
neoamphimedine.[49] Demethyldeoxyamphimedine was 
obtained from the purple chromotype of the Western 
Mediterranean ascidian Cystodytes dellechiajei.[50] The 5-
methoxy derivative of neoamphimedine (R = OMe) was 
obtained together with neoamphimedines Y (R = H) and Z (R 
= Me) accompanied by a new skeleton in alpkinidine (Fig. 5), 
from Xestospongia carbonaria and Xestospongia exigua, 
drawn in such a way as to suggest its possible relationship to 




Figure 5. Structures of amphimedine, neoamphimedine, 
alpkinidine, and related substances.[48-51] 
 
Examinations of various chromotypes of the western 
Mediterranean ascidian Cystodytes dellechiajei all revealed 
the presence of several known pyridoacridine alkaloids and 
from the purple colored morph collected in Catalonia, N-
deacetylshermilamine B (R = H, Fig. 3) and from the green 
colored morph collected in the Balearic Islands, variants 
cystodimine A (R = H) and cystodimine B (R = OH) (Fig. 6).[52] 
Isocystodamine (R = H), N-methylisocystodamine (R = Me) 






and N-methoxymethylisocystodamine (R = CH2OMe)  induce 
the erythroid differentiation of human leukemia K562 cells with 
an ED50 value of 5 nM. They were isolated from a sponge 
Biemna sp. dredged at a depth of 150 m on a sea knoll named 




Figure 6. Structures of cystodamines, isocystodamines and 
arnoamines.[52, 53] 
 
Purification of the bioactive extract of the ascidian Cystodytes 
violatinctus (Solomon Islands) led to the isolation and 
identification of two known alkaloids and shermilamine F (R = 
C(=O)C(Me)=CHMe, Fig. 3), dehydrokuanoniamine F (R = 
C(Me)=CHMe, Fig. 3) and arnoamines C (R = C(Me)=CHMe, 
Fig. 6) and D (R = CH=CMe2).[54] The Indonesian marine 
sponge Biemna fortis yielded a substance named labuanine A 
(Fig. 7).[55] It has activity as a neuronal differentiation inducer 
against a murine neuroblastoma cell line, Neuro 2A. Two cell 
differentiation inducing pyridoacridines from the same sponge 
proved to be N-hydroxymethylisocystodamine (Fig. 6) and 
neolabuanine A (a tautomer of labuanine, Fig. 7) and co-occur 
with other pyridoacridine natural products.[56] 
 
Three alkaloids from the ascidian Lissoclinum cf. badium 
collected off the coast of Papua New Guinea, were identified 
as inhibitors of the Hdm2 E3 activity. Two of them contain the 
pyrido[2,3,4-kl]acridine subunit, tetracyclic diplamine B, and 
pentacyclic lissoclinidine B. The most biologically interesting 
is lissoclinidine B which inhibits ubiquitylation and degradation 
of p53, and selectively kills transformed cells harboring wild-
type p53 (Fig. 7).[57]  
 
Petrosamine B is an inhibitor of the Helicobacter pylori 
enzyme aspartyl semialdehyde  dehydrogenase and  was 
isolated from the Australian sponge Oceanapia sp (Fig. 8).[58] 
The compound is isomeric (position of the bromine) with 
petrosamine, also from a sponge, Petrosia sp.[59] In analysis 
of petrosamine B, these workers found no evidence for the 
dicarbonyl form reported for petrosamine. 
 
However, in another study of petrosamine, isolated from a 
Thai marine sponge Petrosia sp., it was shown to exist in the 
dicarbonyl form in DMSO-d6 solution.[60] Along with 





Figure 7. Structures of labuanine A, neolabuanine A, diplamine B and 
lissoclinidine B.[54] 
 
Petrosamine has potent anticholinesterase activity, six times 
higher than that of the reference galanthamine. In a 
computational docking study, using the enzyme from the 
electric eel Torpedo californica (TcAChE), a major contribution 
was shown to be due to interaction with the N,N-dimethyl 









1,4-Naphthoquinone has been used to generate pentacyclic 
systems and compounds with more than five rings.[61] Thus, 
reaction with TFA-protected kynuramine, 88, leads in two 
steps and in one pot to the pentacyclic quinoneimine 89 





Scheme 27. Synthesis of 4-deaza-ascididemine 89.[61] 
 
The keto-diamine 90 reacts with cyclohexane-1,3-dione to 
generate partially reduced versions 91 quantitatively.[60] 
These can be oxidised to the quinone-imines 92 which react 






with bromine with substitution of both hydrogens of the 




Scheme 28. Synthesis of quinone-imines 92.[61] 
 
A total synthesis of sebastianine A was achieved (Scheme 29) 
starting with a Diels–Alder cycloaddition of 93 with 4,7-
dimethoxyindole-derived quinone 94.[62] The yields in the 
Diels–Alder step were very low. Cyclization in basic conditions 




Scheme 29. Synthesis of sebastianine A.[62]  
 
Another compound with a fused pyrrole ring is arnoamine A, 
a synthesis of which (Scheme 30) can be traced back to the 
quinoline 96.[63] Conversion of amine into diazonium salt and 
reaction with a 1,3-keto-acid (the Japp–Klingemann reaction) 
produced the arylhydrazone 97 which was then transformed 
into pyrido-indole 98 via a Fischer indole synthesis. Rather 
vigorous conditions induced intramolecular indole-N-arylation 





Scheme 30. Synthesis of arnoamine A.[63] 
 
 
The arnoamine skeleton 104 was also produced via a different 
strategy (Scheme 31) in which a preformed N-phenyl indole 
100 was the starting point.[64] Construction of the 4-quinolone 
unit in 102 via thermolysis of the Meldrum’s acid structure 101 
and reaction with phosphoryl chloride gave the chloro 
compound 103. Formation of the final bond relied on an 
intramolecular radical substitution. Work employing this final 




Scheme 31. Synthesis of arnoamine A skeleton from an indole.[65, 66] 
 
The Authors’ synthesis of ascididemine began with the 
acridone 105 (Scheme 32)[67] converted as shown into 
ethynyl-acridine 106. The next step was entirely novel 
involving reaction with sodium diformylamide and producing 
the ‘top’ pyridine ring directly 107. Transformation into a 
bromo-quinone-imine 108 allowed an aza-Diels–Alder 
sequence to complete the synthesis. Analogous methodology 
also produced the non-natural ascididemine isomer 109. A 
tentative mechanism for the key ring-forming step giving 107 





Scheme 32. Synthesis of ascididemine and an isomer 109.[67 
 








Scheme 33. Proposed mechanism of pyridine ring formation from 
alkyne 106 with sodium diformylamide. 
 
Another synthesis of ascididemine, based on oxidative 
amination of a quinone, began with a regioselective reaction 
between quinoline-5,8-dione and the aniline 110 (Scheme 34) 
in the presence of air to oxidise the initial Michael addition 
intermediate to 111. Cyclisation of 111 to the tetracycle 112 
resulted from successive reactions with trifluoroacetic acid 




Scheme 34. Synthesis of ascididemine from quinoline-5,8-dione and 
structure of  4-deaza-ascididemine 89.[68] 
 
The quinoline-5,8-dione employed in Scheme 34 was also 
used in the synthesis of non-natural analogues 117 (Scheme 
35).[69] The quinone was reacted with various ortho-
aminoacetophenones 114 to provide variation in the benzene 
ring, and the products 115 closed to tetracycles 116 with 
strong acid. The ‘top’ ring was constructed by functionalization 
of the pyridine-4-methyl group using DMFDEA and then 
reaction with ammonia (cf. Scheme 18). 
 
For several of the products, the antitumor activity (determined 
in vitro) and tolerability (determined in vivo) were superior to 
those of the alkaloids of which they are analogues. Several 
analogues, as well as ascididemine, bromo-leptoclinidinone, 
neocalliactine acetate, and 11-hydroxy-ascididemine 
themselves, were produced via a Brønsted acid-promoted 
tandem annulation (Scheme 36 – only the intermediates for 




Scheme 35. Synthesis of ascididemine analogues 117 from 
quinoline-5,8-diones 115.[69]  
 
Again here, amino-quinoline-quinones e.g. 118 were utilised 
and prepared, as previously, by amination of the quinone in 
the presence of an oxidising trap. Of several conditions 
assessed, the best to bring about the conversion of 118 into 
the final products proved to be ferric sulfate and sulfuric acid 





Scheme 36. Synthesis of ascididemine via a tandem annulation.[70] 
 
In the light of the bioactivity of ascididemine, several other 
reports describe analogues (only those with a pyrido[2,3,4-
kl]acridine unit are described here). For example, the 4-deaza-
ascididemine 89 was constructed using 119 as starting 
material. Using the Minisci reaction, 4-methyl-3-
cyanoquinoline was converted into the ketone 119. 
Functionalisation of the methyl group produced a 2-pyridone 
unit and conversion into halide 120 allowed a radical, but low 





Scheme 37.  Synthesis of 4-deaza-ascididemine 89 via a radical 
aromatic substitution.[71] 
 
Adapting the approach further, naphthyridine ester 121 was 
produced via Minisci substitution, which was cross-coupled 
with various aryl- and hetarylboronic acids (only product 122 
from phenylboronic acid is shown) to give materials ready for 
a final strong acid-promoted closure, in this case giving 89 
(Scheme 38).[72] Amongst several other structures produced 
in this way were 123 and 124. 









Scheme 38. Synthesis of 4-deaza-ascididemine 89 and structures of 
analogues 123 and 124.[72] 
 
Reversing the sequence of bond formations, the ester 125, 
and substituted variants (not shown), were made by cross-
coupling 4-bromobenzo[c][2,7]naphthyridine with aryl esters 
carrying an ortho boronic acid, and the last ring made via 
metallation at the N=CH with 2,2,6,6-tetramethylpiperidinyl-
magnesium chloride lithium chloride complex (TMPMgCl·LiCl), 
though in only moderate yields (Scheme 39).[73] The isomers 




Scheme 39. Synthesis of 4-deaza-ascididemine 89 and structures of 
ascididemine isomers 126 and 109.[73] 
 
The base-promoted closure of two rings using sodium hydride 
in N,N′-dimethylpropyleneurea (DMPU) from the fluoro-nitrile 
127 neatly leads directly to 4-deaza-ascididemine 89, with 
formation of two rings, though the yields in this example and 
substituted variants, were only moderate (Scheme 40).[74] The 





Scheme 40. Synthesis of 4-deaza-ascididemine 89.[74] 
 
 
The non-natural isomer 109 of ascididemine  was also 
prepared  as  shown  in Scheme   41.[75] Firstly  the  dimethoxy- 
methylacridine 128 was constructed and converted into the 
corresponding quinone 129. Aza-Diels–Alder reaction with 
acrolein N,N-dimethylhydrazone added  the next pyridine ring. 
Functionalisation of the methyl group by reaction with 
DMFDEA (130) and then simple treatment with aqueous 




Scheme 41. Synthesis of non-natural isomer 109 of ascididemine.[75]  
 
Somewhat further away from natural structures, the hydro-
pyrido[2,3,4-kl]acridines 133 were prepared (Scheme 42) and 
shown to be cytotoxic, but no strict correlations with their DNA 
binding affinity and effects on topoisomerases were 
observed.[76-78] The construction was very straightforward, 
having in hand the amino-ketones 132 and ketones 131, 




Scheme 42. Synthesis of pentacyclic pyridoacridines 133.[77] 
 
The first total synthesis (Scheme 43)[79] of neoamphimedine 
proceeded with the construction of the 4-(2-
nitrophenyl)dimethoxyquinoline 134 originating from 4-
methoxy-2-nitrophenol in seven steps.  Transformation of the 
acetylamino group of 134 into carboxylic acid 135  and 
formation of an amide with N-methylaminoacetaldehyde 
dimethylacetal gave 136, which was ring closed in acidic 
media.  Nitro-group reduction and then reaction of the 
resulting aniline with the quinone, produced by oxidation with 
CAN of the dimethoxybenzene, gave the last heterocyclic ring 
of neoamphimedine. 








Scheme 43. First synthesis of neoamphimedine.[79] 
 
In a somewhat shorter route to neoamphimedine, described 
as an ATP-competitive inhibitor of topoisomerase IIα and 
potent anticancer agent, key intermediate 136 was 
constructed via a triflate cross-coupling with stannane 137 
(Scheme 44).[80] Hydrolysis of ester then formation of amide 
bond was achieved by reaction N-methylaminoacetaldehyde 
dimethyl acetal using as activating agent propylphosphonic 
anhydride (T3P). Arguably, neoamphimedine is one of the 
most potent antitumor agents of the pyridoacridine family.[6]  
 
 
Scheme 44. Improved steps in a synthesis of neoamphimedine.[80] 
 
In a delightfully short synthesis (Scheme 45)[81] of 
amphimedine, kynuramine gained from tryptamine via an 
improved route, was converted directly into styelsamine D. 
Next, reaction with formaldehyde generated a mixture of 
demethyldeoxyamphimedine and deoxyamphimedine. The 
final step was the oxidation of the pyridinium salt with 
ferricyanide – fortunately this occurred on the desired side of 
the quaternary nitrogen giving amphimedine. 
 
Another synthesis of demethyldeoxyamphimedine required, 
impressively, only four steps starting from ethyl nicotinate and 
2-iodoaniline (Scheme 46).[82] Cross coupling of the 4-
metallated ethyl nicotinate 138 with 2-iodoaniline produced 




Scheme 45. Syntheses of styelsamine D, demethyldeoxyamphime-
dine, deoxyamphimedine, and amphimedine.[81] 
 
Conversion into bromide 140 and cross coupling with the 
same metallated nicotinate produced 141 requiring only 
metallation of the pyridine moiety using TMPMgCl·LiCl, for 
intramolecular nucleophilic attack on the ester and the 




Scheme 46. Synthesis of demethyldeoxyamphimedine.[82] 
 
An elegant use of gold catalysis with chloro(triphenyl-
phosphine)gold(I) brings about ring closure (formation of two 
rings) of alkynyl-anilines 142 to iminoquinone 143 (Scheme 
47).[83] The starting amino-quinones 142 were prepared from 
the quinoline-5,8-dione and the aralkynylmethylamine under 
oxidative conditions to trap initial adducts. Comparable deaza-






Scheme 47. Synthesis of compounds 142 and 144.[83] 
 
 






A simple synthesis of subarine from a Singapore ascidian[46] 
employs a cross-coupling as a key step (Scheme 48).[84]  The 
structure is drawn in such a way as to suggest its relationship 
to the pentacyclic alkaloids of the ascididemine group, but with 
one ring ‘missing’ – hence its inclusion, though tricyclic, in this 
Section. Oxidative cleavage of the benzene ring in 4-bromo-
1,10-phenanthroline 145 and esterification of the resulting di-
acid gave di-ester 146. Cross-coupling with N-(tert-
butoxycarbonyl)-2-(trimethyl stannyl)aniline produced 147 
then converted into the alkaloid with acid. 
 
 
Scheme 48. Synthesis of subarine.[84] 
 
A second and somewhat shorter synthesis of subarine also 
began with an oxidative cleavage, leading to dimethyl [2,2'-
bipyridine]-3,3'-dicarboxylate 148 (Scheme 49).[85] Amide 
formation with 2-iodoaniline to 149 and a final carbon–carbon 
bond-forming radical step gave the alkaloid, though only in 7% 
yield for the last step.[86] 
 
 
Scheme 49. Second synthesis of subarine.[86] 
 
3.2.3. Helicenes and triazatriangulenium salts  
 
The highly configurationally stable [4]heterohelicenium 
cations, e.g. 150, can be prepared from the triaryl carbocation 
151 by reaction with an amine, e.g. n-propanamine, four of the 
methoxy groups being thus displaced (Scheme 50).[87] The 
displacement of one pair of methoxy groups takes place at 
50 °C.[88] Interference between the remaining methoxy groups 
in salts such as 150 ensures that the helicity is maintained. 
The salt 150 was shown to be configurationally stable up to 
200 °C. Compound 150 was resolved by forming 
diastereomeric salts with  binphat. Under strongly acidic 
conditions, e.g. PPA (polyphosphoric acid) or Eaton’s reagent 
(phosphorous pentoxide in methanesulfonic acid), 
regioselective electrophilic substitution of salts such as 150, 
e.g. acylations, sulfonylations, or alkylations, occurs at the 
extremity of the helical cores, ortho to a methoxyl group.[89] A 
range of nucleophiles, including aryl- and alkyllithiums, and 
hydride,  react  with  these  salts  with  attack   at   the   central  
 
positively charged carbon, to produce neutral products, as in 
the examples 152 and 153 shown in Scheme 50. Derivatives 
with substituents at the central carbon such 154 can also be 
obtained via lithiation of the hydride reduction product 153. 





Scheme 50. Synthesis and reactions of [4]heterohelicenium 
cations.[87] 
 
The use of hydrazine instead of a primary amine in reaction 
with carbocations 155 allows the synthesis of neutral products, 
with a fully aromatic acridine unit, but still chiral, quinacridines 
157.[91] As illustrated in Scheme 51, the products 155 of 
disubstitution with one primary amine unit, react with 
hydrazine giving intermediates believed to have structures 
156 and then cleavage of the N–NH2 bond brings about 
aromatization of the central pyridine ring (arrows on 156 are 
suggested). Quinacridines 157 are pink and when protonated 




Scheme 51. Synthesis of chiral 5H-quino[2,3,4-kl]acridines 157.[91] 
 
Under more extreme conditions, the triaryl carbenium ions 151 
can be made to react with three equivalents of primary amines 
to produce cations called ‘triazatriangulenium’ ions (Fig. 9), 
e.g. the dark blue 158 (n-PrNH2, NMP, 110 °C, 77%).[92] 
 
 









Figure 9. Typical triazatriangulenium cations 158-160.[93] 
 
Even more extreme conditions are required to introduce three 
arylamines, thus  151 tris(2,6-dimethoxyphenyl) methylium ion 
(DMP3C+) was heated in excess of various anilines, in the 
presence of sodium hydride, in a solvent-free reaction at 
210 °C producing 159.[93] Triazatriangulenium cations 160 
with longer R groups, prepared with amines at 180 °C, can be 
used as phase-transfer catalysts.[94] 
 
Aryl- and ethynyllithiums add easily to the central, positively 
charged carbon of triazatriangulenes, giving neutral 
products.[95] This process can be reversed photochemically.[96] 
Analogous systems, with one oxygen and two nitrogens as the 
bridging heteroatoms, can also be prepared, for example 
starting from salt 155. Thus ‘diazaoxatrianguleniums’ 162 
were made via demethylation of a methyl ether in a salt 161 
then intramolecular displacement of the remaining methoxyl 
by the so-formed phenolic oxygen, as shown in Scheme 52.[97] 
Electrophilic substitution of diazaoxatriangulenes such as 162, 
for example nitration and Vilsmeier formylation, occurs on the 
benzene ring with two nitrogens attached, and ortho to a 
nitrogen.[98] A study of the interaction of trianguleniums as 
optical probes for G-quadruplexes, showed 163 to be a unique 
fluorescence probe.[99] Interaction with a G-quadruplex from 
the promoter region of the c-myc oncogene revealed that they 
interact at 1:2 binding stoichiometry. Calculations showed that 
binding occurs mainly through  stacking between the 











3.3. Hexacyclic systems 
 
Several hexacyclic alkaloids containing the pyrido[2,3,4-
kl]acridine motif have been isolated during the 21st Century. 
Cycloshermilamine D was isolated from the marine tunicate 
Cystodytes violatinctus.[101] Segoline C possessing the benzo 
1,6-diazaphenanthroline ring system was isolated from the 
Indian Ocean tunicate Eudistoma bituminis together with the 
known segoline A  previously isolated from the Red Sea 




Figure 10. Structures of cycloshermilamine D, segolines A, C, 
sebastianines A, B and nordehydrocyclodercitin.[101-104] 
 
Sebastianine A (cf. Scheme 29 for synthesis) and 
sebastianine B were new alkaloids from the ascidian 
Cystodytes dellechiajei collected in Brazil.[103] 
Nordehydrocyclodercitin, from the ascidian Aplidium 
cratiferum was collected at Arab Reef, Great Barrier Reef, 
Australia.[104] 
 
Hexacyclic acridine dye 169 possessing remarkable 
fluorescence properties and absorbing in the green area of the 
spectrum was synthesized from bromoacridone 164 (Scheme 
53).[105 ] A palladium-catalysed Buchwald–Hartwig coupling 
between 164 and  monoprotected ortho-phenylenediamine 
165  produced 166. Successive closure of the benzimidazole 
ring in refluxing acetic acid and quaternisation in refluxing 
methyl iodide gave the benzimidazolium-acridone 167. 
Treatment of N-methylacridone 167 with a mixture of thionyl 
chloride and a few drops of anhydrous DMF gave the unstable 
9-chloroacridinium chloride 168 that was converted in situ into 
the desired hexacyclic acridinium salt by addition of 
triethylamine which produced a 2-methylene-benzimidazole 
allowing attack on the acridine C-9 position. Dye 169 was 
finally isolated as a hexafluorophosphate salt by anion 
interchange after treatment with sodium hexafluorophosphate. 
 








Scheme 53. Synthesis of acridine dye 169.[105] 
 
Imidazoquinolinoacridones 171 were obtained with good 
yields by a three-component reaction of 2-halo aromatic 
aldehydes, benzimidazol-6-amine 170 and cyclohexane-1,3-
diones, catalyzed by copper(I) iodide and L-proline (Scheme 
54).[106] The same domino reaction was applied for the 
syntheses of pyrazolo and triazolo derivatives 172 and 173 
using as starting material a indazole-6-amine or a 




Scheme 54. Syntheses of imidazoquinolinoacridones 171 and 
structures of hexacyclic acridones 172 and 173.[106-108] 
 
Reaction of 1,4-naphthoquinone with keto-diamine 174, in the 
presence of an oxidizing agent, forms firstly 175, which can be 
ring closed with ammonia, as a base, to the hexacyclic 176 
(Scheme 55). In studies of electrophilic substitution, it was 
found that nitration occurs ortho to the methoxyl groups in 176 




Scheme 55. Synthesis of benzo[b]quino[4,3,2-mn]acridin-10-ones 
176.[61] 
 
3.4. Heptacyclic systems 
 
A total synthesis of the heptacyclic pyridoacridine alkaloid 
eilatin and its isomer isoeilatin was performed starting from 
pyridoacridones 78 or 181 respectively.[109] The 
pyridoacridone 78 was obtained (Scheme 56) by 
condensation of acridone 177 with DMFDEA (cf. Scheme 18) 
followed by ring closure with hydroxylamine hydrochloride to 
give the N-oxide 178. Rearrangement of N-oxide 178 using 
acetic anhydride gave an acetoxy derivative, which was 
hydrolyzed to alcohol 179. Subsequent oxidation of 179 gave 




Scheme 56. Synthesis of 4H-pyrido[2,3,4-kl]acridin-4-one 78.[109] 
 
Oxidative amination of 78 with 2-aminoacetophenone using 
cerium(III) chloride catalyst followed by cyclization gave the 
hexacyclic pyridoacridone 180 which was transformed into 
eilatin by an annulation reaction using another DMFDEA 
procedure (Scheme 55). 
 
The same oxidative amination on pyridoacridone 181, 
cyclization and annulation afforded isoeilatin 182 (Scheme 57). 
 
There has been substantial interest in metal complexes of 
eilatin; structure 183 [Ru(bpy)2eilatin] shows which nitrogens 
are used when the alkaloid acts as a mondentate ligand 
(Scheme 58).[110]  However, the alkaloid can also act in a 
bidentate fashion, as in the complex 184.[111] Eilatin Ru(II) 
complexes display anti-HIV activity and enantiomeric diversity 
in the binding of RNA.[112] 
 








Scheme 57. Syntheses of eilatin and isoeilatin 182.[109] 
 
The cationic [Fe(eilatin)3]2+ effectively recognize 
(tris(tetrachlorobenzenediolato)phos-phate(V) (TRISPHAT) 




Scheme 58. Structure of ruthenium complexes of eilatin in mono- and 
bidentate modes.[110, 111] 
 
4.    Pyrido[2,3-a]acridine 
{benzo[j][1,7] phenan-throline}   
 
There seem to be no natural products that include the 
pyrido[2,3-a]acridine  nucleus however, there are synthetic 
examples. Benzylic carbanions react with nitroarenes under 
mild conditions in the presence of DBU and 
trialkylchlorosilanes to form tetra- and pentacyclic azaarenes. 
This process was used to construct the cyano-pyrido[2,3-




Scheme 59. Synthesis of a cyano-pyrido[2,3-a]acridine 185.[114] 
 
The proposed mechanism for the synthesis of pyridoacridine 
185 is shown in Scheme 60. Addition of benzylic carbanion to 
the nitroquinoline gives I-1 which was transformed via I-2 into 
I-3 ready for an electrocyclization and aromatization to afford 




Scheme 60. Proposed mechanism for the reaction of benzylic 
carbanions with nitroarenes.  
 
A three-component process involving an aromatic aldehyde, 
dimedone and 7-aminoquinoline produces hexahydropyrido 




Scheme 61. Synthesis of hexahydropyrido[2,3-a]acridinones 186.[115] 
 
Condensation of the quinolin-4-one 187 with 2-
chloroquinoline-3-carbaldehyde 188 gave an alkene 189 
which could be ring closed to 190 with base (Scheme 62).[116] 
 
The synthesis of the heptacyclic ‘triazatrinaphthylene’ 192 
(TrisK), a three-fold symmetry planar conjugated system with 
two-dimensional self-assembly properties, is an extension of 
the approach described for the synthesis of 220 (Scheme 76) 
and 288 (Scheme 95). In the present context, product 191 
obtained by Buchwald-Hartwig cross-coupling between 1,3,5-
tribromobenzene  and 2-amino-5-methylbenzoic acid, triply 
cyclised with phosphoryl chloride leading to 192 via a 
heptacyclic  triketone, reduced to a hexahydro-heptacycle 
then aromatized with iron(III) chloride (Scheme 63).[117] 









Scheme 62. Synthesis of substituted dibenzo[b,j][1,7]phenanthrolin-
14-ones 190.[116] 
 
The structure actually contains three pyrido[2,3-a]acridine and 
three pyrido[2,3-c]acridine moieties. Exactly comparable 
triazatrinaphthylenes were prepared starting from 2-amino-5-
alkoxy(C3H7O; C10H21O; C12H25O; C16H33O)benzoic acid.[118] 
  
The compounds with propyloxy substituents, and its precursor 
still with three chlorine atoms (193, Scheme 64) were shown 
to form  highly organized nanoporous honeycomb networks 
when adsorbed at the n-tetradecane/HOPG (highly oriented 




Scheme 63. Synthesis of a diquino[2,3-a:2',3'-c]acridine 192.[117] 
 
Displacements of the chlorines in 193 with amino-substituents 
(e.g. NH(CH2)2NMe2) produced substances that recognize G-
Quadruplex DNA.[120,121] The displacement of chlorines with 
other amines gave substances 194 that react (Scheme 64) 




Scheme 64. Synthesis of triamino-diquino[2,3-a:2',3'-c]acridine boron 
adducts 195.[122] 
A variant on these ring closures, that provides fully aromatic 
products directly, depends on the use of ortho-
arylaminophenyl Schiff bases.[123] Thus, in a general study, 
one example had 196 being converted into 197 (R = H). 
Perhaps even simpler, the diketone 198 was ring closed to 
197 (R = Me) under acidic conditions (Scheme 65).[124]  
 
 
Scheme 65. Two approaches to dibenzo[b,j][1,7]phenanthrolines 
197.[124] 
 
6,7-Dihydrodibenzo[b,j][1,7]phenanthrolines 202, which 
contain both a pyrido[2,3-c]acridine  unit and a pyrido[2,3-
a]acridine moiety, can be assembled using an efficient two-
step procedure, summarized in Scheme 66.[125] An aldol 
condensation between the tetrahydroacridone 199 and an 
ortho-nitro-araldehyde 200 giving an alcohol 201 is followed 
simply by conditions to reduce the nitro group to amine (iron 
and acetic acid), cyclisation and loss of water in the acidic 
conditions, in situ, completing the sequence. A selection from 
the twenty-five examples given in the paper is shown in the 
Scheme 66. Aromatisation of the remaining partially saturated 




Scheme 66. Synthesis of substituted dihydro-dibenzo[b,j][1,7] 
phenanthrolines 202.[125] 
 
The pentacyclic compounds 203 were prepared as shown in 
Scheme 67. The  luminescence spectra in solution and 
polycrystalline state were studied.[126] 
 
 
Scheme 67. Synthesis of dihydro-naphtho[2,1-j] [1,7]phenanthrolines 
203.[126] 







5 .   Pyrido[3,4-a]acridine  
{benzo[j][2,7] phenanthroline}   
 
No natural products containing this tetracyclic system have 
been reported and there are no simple synthetic examples. 
 
6.  Pyrido[4,3-a]acridine  
{benzo[j][3,7] phenanthroline}   
 
There has been no synthetic work to produce this isomer, and 
no natural substances incorporating this skeleton have been 
reported. 
 
7.  Pyrido[3,2-a]acridine  
{benzo[b][4,7] phenanthroline}   
 
Here again there are no natural substances that include this 
skeleton, however there are synthetic examples. The reaction 
of 6-aminoquinoline 204 with cyclohexane-1,3-diones and 
formaldehyde produces partially reduced pyrido[3,2-
a]acridinones  205 (R2  = H, Scheme 68).[127]  Inclusion of  an 
araldehyde in the reaction mixture, instead of the 
formaldehyde, produces corresponding products 205 (R2 = Ar; 




Scheme 68. A simple synthesis of hexahydropyrido[3,2-a ]acridino-
nes  205.[127] 
 
Benzylic carbanions react with nitroarenes under mild 
conditions in the presence of DBU and trialkylchlorosilanes to 
form tetra- and pentacyclic azaarenes. This reaction was used 
to make a range of fused systems from 6-nitroquinoline 
including cyano- 206 and methoxycarbonyl- 207 pyrido[3,2-
a]acridines (Scheme 69).[114] For a discussion of the 




Scheme 69. The use of benzylic anions and 6-nitroquinoline to 
prepare pyrido[3,2-a]acridines and naphtho[1,2-b][4,7]phenanthro-
lines. [114] 
 
Reaction of 5-amino-1,10-phenanthroline 208 with 
formaldehyde and acid produced the tetrapyrido[3,2-a:2',3'-
c:3'',2''-h:2''',3'''-j]acridine 209 subsequently designated ‘tpac’ 
(Scheme 70).[129] The use of microwave heating reduced the 
synthesis reaction time from a week to 60 minutes – 70% 
yield.[130] The extended polycyclic bis-phenanthroline ligand 
led to the use of tpac in the formation of several metal 
complexes, in a monodentate or bidentate fashion (see 
below). Note: the structure of tpac comprises two pyrido[3,2-




Scheme 70. Synthesis of tpac 209.[129] 
 
The synthesis is interpreted as beginning with electrophilic 
substitution ortho to the amino group of 5-amino-1,10-
phenanthroline 208 leading to alcohol I-1, loss of water from 
which  ( I-2) and attack by a second equivalent of starting 
amine then producing I-3. Final acid-catalysed cyclising 




Scheme 71. Postulated mechanism of the synthesis of tpac from 5-
amino-1,10-phenanthroline 
 
Analogous mono-dentate ligands 211, the prototype being 
benzo[b]pyrido[3,2-f][1,7]phenanthroline (bpp) itself 211 (R1 = 
R2 = H), were prepared using 2-amino benzyl alcohols 210 




Scheme 72. Synthesis of benzo[b]pyrido[3,2-f][1,7]phenanthrolines  
211.[131] 
 
Typical of the type of structure for complexes that have 
incorporated such ligands is 212, Ru(phen)2(bpp) (Scheme 
73).[131] Examples of the utility of complexes incorporating the 
ligands described above are the following: the complex 
Cu(tpac)2Cl was shown to cleave supercoiled pUC18 plasmid 
DNA in an oxidative manner by photoactivation with visible 
light;[132] the rigid dinuclear [(tap)2Ru(tpac)Ru(tap)2]4+ complex 
(tap = 1,4,5,8-tetraazaphenanthrene) efficiently 
photodamages oligodeoxyribonucleotides containing 
guanine.[133] A review covers ‘Ruthenium(II) complexes 
bearing fused polycyclic ligands: from fundamental aspects to 






potential applications’ and includes complexes involving 
ligands in this section, and others.[134]  
 
The complex [Ru(bpp)(bpy)2]2+, underwent 2e– and 2H+ 
reduction, generating [Ru(bppHH)(bpy)2 ]2+, in response to 
visible light irradiation in solution in aqueous acetonitrile with 
triethylamine.[135]  The pyridine ring of the acridine unit was 




Scheme 73. Formation of a ruthenium complex 212 of bpp.[131] 
 
A complex containing a tpac unit was made by synthesis using 
a preformed ruthenium complex. Thus, [(tap)2Ru(5-amino-
1,10-phenanthroline] gave [(tap)2Ru(tpac)]2+ by reaction with 
5-amino-1,10-phenanthroline and formaldehyde promoted by 
6 M hydrochloric acid at 90 °C (compare with the method in 
Scheme 70).[136] 
 
An entirely different type of complex 216[137]  was prepared 
from primary amine 214 by reaction with platinum source 215. 
Scheme 74 shows how 2-methyldibenzo[b,j][4,7] 
phenanthroline 213[136] was converted into 216 in five steps. 
The complex 216 interacts with quadruplex DNA via a dual 




Scheme 74. Formation of a platinum complex 216.[137] 
 
Several polycyclic aza-aromatic compounds were produced 
via cyclization reactions of ortho-arylaminophenyl Schiff 
bases e.g. 217, promoted by zinc chloride, one example 
producing the quinacridine 218[123] (quinacridines are 
pyridoacridines with an extra fused benzene ring) as is shown 
in Scheme 75. Coordination of each imine nitrogen to zinc 
chloride activates the system for two intramolecular 
electrophilic cyclizations, with subsequent elimination of two 




Scheme 75. Conversion of ortho-arylaminophenyl Schiff base 217 
into a quinacridine 218.[123] 
 
Quinacridines can also be assembled in a stepwise fashion. 
Thus, Buchwald-Hartwig cross-coupling of iodoaniline 219 
and methyl anthranilate produced a diester, double ring 
closure with phosphoryl chloride after ester hydrolysis then 
giving the dichloro-pentacycle 220; the halogen could be 
removed but at the expense of reduction of one of the rings, 
affording 221, but this is easily aromatized to give 2-




Scheme 76. The assembly of a dihydro-quinacridine 221 from methyl 
anthranilate.[138] 
 
Making the same two bonds to reach quinacridine 223 can be 
achieved easily using dialdehyde 222 and indium triflate, 




Scheme 77. A synthesis of dibenzo[b,j][4,7]phenanthroline 223.[139] 
 
The cyclisation substrate 225 was prepared by benzyne 
insertion into para-phenylenediamine-bis(trifluoroacetamide) 
224. Double ring closure to 226 was secured with hot 
trifluoroacetic acid.[140]  An exactly comparable double ring 
closure but with methyl instead of trifluoromethyl, was brought 
about with catalytic sulfuric acid in refluxing acetic acid.[121]  
Product 226 can also be accessed via reaction of ortho-
aminophenyl trifluoromethyl ketone with cyclohexane-1,4-
dione giving 227, easily dehydrogenated (Scheme 78). The 
formation of 227 can be seen as a double Friedländer reaction. 








Scheme 78. Two syntheses of dibenzo[b,j][4,7]phenanthroline 
226.[140-141] 
 
The condensing cyclisations of N,N'-diphenyl-para-
phenylenediamine 228 with carboxylic acids or dicarboxylic 
acids, produces helical species, by virtue of the steric 
interference between the R1 groups or constraint from the 
introduced ring; structures 229 and 230 are examples 




Scheme 79. Syntheses of helical dibenzo[b,j][4,7]phenanthrolines 
229 and 230.[141] 
 
8.  Pyrido[2,3-b]acridine   
 
There is very little published work on simple (tetracyclic) 
examples of this ring structure. The patent literature contains 
many examples of elaborated versions with extra benzene/ 
pyridine ring(s) fused, but these are not discussed here. 
 
Alkaloids such as deoxyascididemine and eilatin (Fig. 4) from 
the Australian ascidian Polysyncraton echinatum, contain 
both pyrido[2,3-b]acridine and pyrido[2,3,4-kl]acridine  nuclei 
and all the other examples of this situation are considered 
under the latter heading.[142] Quinones 231[143] and 232[144] 
were amongst several re-prepared to assess antituberculosis 




Figure 11. Structures of benhamycin and related compounds.[142-146] 
 
9.  Pyrido[3,4-b]acridine  
 
There has been no synthetic work on this isomer, but there is 
an ‘intensely yellow’ alkaloid, isolated from a terrestrial 
Streptomyces sp., which incorporates the skeleton and was 
named benhamycin (Fig. 11).[146] The compound has an 
additional fused benzene ring in the pentacyclic structure 
which was established by spectroscopic analysis, including 
extensive 1H and 13C NMR measurements.  
 
10.  Pyrido[4,3-b]acridine  
 
There has been little synthetic work on this isomer, and no 
natural substances incorporating this skeleton have been 
reported. 
 
The quinone 235 was constructed from the isoquinoline-
quinone 233[147] thus, reaction with 2-aminoacetophenone in 
the presence of cerium trichloride produced 234 and this was 
ring closed to 235 in acid. A fifth ring was added utilizing the 
reactivity of the methyl group, located as it is at C-4 of the 
pyridine unit, and in the process producing a product 236  
(Scheme 80) which now also has a pyrido[2,3,4-kl]acridine 




Scheme 80. Construction of a pyrido[4,3-b]acridine-5,12-dione 235 
and its conversion into 9H-quino[4,3,2-de][1,8]phenanthrolin-9-one 
236. [147] 
 
11.   Pyrido[3,2-b]acridine   
 
There are no relevant examples of compounds containing this 
structure and there are no natural products either. 
 
12.  Pyrido[2,3-c]acridine  
{benzo[b][1,7-phenanthroline}   
 
Note: the chemistry of tpac 209 (Scheme 70) which includes 
both two pyrido[2,3-c]acridine and two pyrido[3,2-a]acridine 
units, is dealt with in the pyrido[3,2-a]acridines, Section 7. 
 
In work to prepare analogues of the pyranoacridone alkaloid 
acronycine, fromAcronychia baueri Schott (Rutaceae), which 
has antitumor properties, the tetracyclic acridone 238 was 
assembled, the key step being the intramolecular aroylation 






(237238) (Scheme 81).[148] Using 1-bromonaphthalene-2-





Scheme 81. Synthesis of an analogue 238 of acronycine.[148] 
 
Amine 240[150] was converted into the synthetically useful 
aldehyde 242 as shown in Scheme 82.[151] The formation of 





Scheme 82. Introduction of an aldehyde function at C-11 of a 
pyrido[2,3-c]acridine 242.[151]  
 
A range of diamine ligands, e.g. 244, based on meta-
quinacridine were prepared and evaluated for their G-
quadruplex binding properties.[152] The Scheme 83 shows how 
methyl substituents were oxidized to aldehyde (55% for 
oxidation of 243) and then reacted with various amines (n-
PrNH2, Me2N(CH2)2NH2, imidazol-3-yl(CH2)2NH2, indol-3-
yl(CH2)2NH2, etc.) followed by sodium borohydride reduction; 
structure 244, for example, one of thirteen prepared, was 
formed in 28% yield for the last two steps. Comparable 
diamines were attached to two aminoglycosides, one such 





Scheme 83. Oxidation of methyl groups on a 
dibenzo[b,j][1,7]phenanthroline.[152] 
 
13.  Pyrido[3,4-c]acridine 
{benzo[b][1,8] phenanthroline}    
 
Note, that natural products related to amphimedine (Fig. 5), 
for example petrosamine B (Fig. 8) incorporate both 
pyrido[3,4-c]acridine and pyrido[2,3,4-kl]acridine units; they 
are dealt with in Section 3 on pyrido[2,3,4-kl]acridines. 
 
Simple examples of pyrido[3,4-c]acridines were prepared, as 
potential amebicides,[154] as potential antitumor agents,[155] as 
antileukemia agents,[156] earlier than the period under review, 
but are usefully summarized briefly here. Each piece of work 
utilized essentially the same synthetic strategy, shown in 
Scheme 84. Compound 246 was obtained by Ullmannn 
reaction of 2-iodobenzioc acid and 5-aminoisoquinoline to the 
acid 245, ring closure with hot concentrated sulfuric acid and 
then conversion of the resulting ketone into 246 with 
phosphoryl chloride. The chlorine in 246 was displaced with 




Scheme 84. Synthesis of a chloro-pyrido[3,4-c]acridine 246.[155] 
 
In the 21st Century, the ring system has been produced 
incidentally in studies of helical substances in the context of 
supramolecular chemistry and catalysis – various [5]heli-
viologen isomers were produced by quaternisations.[157-159] 
The construction of precursors 247 for photochemical 
cyclisations was achieved with a Hiyama–Heck coupling of a 
3-bromoquinoline and vinyltriethoxysilane. Two isomers 248 
and 249 were formed in the photo-cyclisation and aerial 
oxidation (Scheme 85). The one with the embedded 
pyrido[3,4-c]acridine nucleus 248 underwent mono N-
alkylation at the accessible nitrogen giving salt 250, but 
required the presence of DBU to prevent protonation of the 
‘cove’ nitrogen, possibly by adventitious fluoroboric acid. 
 
 
Scheme 85. Construction of a dibenzo[b,k][1,8]phenanthroline 248 
and its quaternisation.[159] 






14.   Pyrido[4,3-c]acridine 
{benzo[b][1,9] phenanthroline}    
 
There has been no synthetic work to produce this isomer and 
no natural substances incorporating this skeleton have been 
reported. 
 
15.   Pyrido[3,2-c]acridine  
{benzo[b][1,10] phenanthroline}   
 
4-Aminoacridine-3-carbaldehyde 252 has been the starting 
point for the preparation of several pyrido[3,2-c]acridines and 
is itself prepared from 3-methylacridine, as shown in Scheme 
86.[160] Regioselective nitration and reaction with DMFDMA (cf. 
Scheme 18) produces 251. Next, periodate cleavage of the 
enamine double bond and reduction of the nitro gave 252. 
Friedländer synthesis using 252 with aryl methyl ketones 
produces 2-aryl products 253 in high yields. Reaction of 252 
with triacetylmethane gives a mixture of 2-methylpyrido[3,2-
c]acridine (254, R = Me) and pyrido[3,2-c]acridine (254,  R = 
H) itself.[161]  
 
Scheme 86. Synthesis of pyrido[3,2-c]acridines 253 and 254.[161, 161] 
 
Extending the method further to benzo[b]cycloalkanones and 
3,4-dihydro-1(2H)-anthracenone, produced structures 255 
and 256, respectively (Fig. 12);[162] aromatisation of 256 was 




Figure 12. Structures of pyrido[3,2-c]acridines 255-258.[162, 163, 165] 
Extrapolation to pyrido[b]cycloalkanones similarly provided 
products 257 and full aromatization of the product with R = 
(CH2)2 was achieved with Pd/C in nitrobenzene at 200 °C.[163]  
A study of the reactions of ligands 257 with ruthenium(III) 
chloride trihydrate produced complexes of the form [Ru(L)2]2+ 
in favourable cases.[164] Reaction of two equivalents of the 
amino-aldehyde 253 with cycloheptane- and cyclooctane-1,2-
diones produced structures 258.[165] The use of simpler 1,2-
diones gave complex mixtures from which some pyrido[3,2-
c]acridine could be isolated. 
 
Diacetyl benzenes were also subjected to the Friedländer 
sequence with amino-aldehyde 252. This produced intriguing 





Figure 13. Products 259-261 from Friedländer reactions of 
diacetylbenzenes and 4-aminoacridine-3-carbaldehyde 252.[166] 
 
As a final example of the use of the Friedländer reaction using 
252, 2-acetyl-9,9'-spirobifluorene 262 was converted into 263 
in 74% yield (Scheme 87).[167] Reaction with 2,2'-diacetyl-9,9'-




Scheme 87. Product 263 from Friedländer reaction of a spiroketone 
262 with 4-aminoacridine-3-carbaldehyde 252.[167] 
 
8-Aminoquinoline-7-carbaldehyde 264 has also been used in 
Friedländer reactions to enter this series of pyridoacridines 
(Scheme 88). In the simplest case, with cyclohexanone, the 
tetrahydro-derivative 265 is formed.[169] With 1-tetralone, 266 
is formed and with 9,10-dihydrobenzo[a]pyren-7(8H)-one, 
structure 267 results.[170] Cyclohexane-1,2-dione produces 
268 incorporating two equivalents of 264 [166] and reaction with 
5,6,7,8-tetrahydroquinolin-8-one gives 269,[170] precursor to 
dipyridoacridine 270. 








Scheme 88. The use of 8-aminoquinoline-7-carbaldehyde 264 and 
various six-membered ketones to prepare polycyclic ligands 265-
270.[169, 170, 173] 
  
The amino-aldehyde 264 was combined with the bis-tetralone 
271 to prepare the chiral helicene-like 272 and iron and 





Scheme 89. Chiral product 272 from Friedländer reactions of a bis-
tetralone 271 with 8-aminoquinoline-7-carbaldehyde 264.[171] 
 
2-Amino-3-methoxybenzaldehyde is a third ortho-amino-
aldehyde that has been used to construct pyrido[2,3-
c]acridines. Thus, with 5,6,7,8-tetrahydroquinolin-8-one 273 
compound 274 was produced, with the idea that 
dehydrogenation and demethylation would produce a strong 
ligand in the tradition of 8-hydroxyquinoline (Scheme 90). 
Unfortunately, during attempted ether cleavage with hydrogen 





Scheme 90. Friedländer reaction of 5,6,7,8-tetrahydroquinolin-8-one 
273 with 2-amino-3-methoxybenzaldehyde.[172] 
 
Dipyrido[4,3-b;5,6-b]acridine[173] (dpa) 270, often referred as 
‘dipyridoacridine’, can be considered a tridentate homologue 
of 1,10-phenanthroline. The ‘preorganised’ donor nitrogens 
make for strong coordination to larger cations such as Ca2+ 
(structure 275) and La3+.[174] A furan-substituted tetrahydro-
dpa 277 was made by reacting iminium salt 276 with two 




Scheme 91. Quino[8,7-b][1,10]phenanthrolines complex large 
cations.[175] 
 
A classical pyridine ring synthesis (279280) provided 
unsymmetrically substituted tetrahydro-dpas such as 280, 
illustrated in the Scheme 92 with 5,6,7,8-tetrahydroquinolin-8-




Scheme 92. Synthesis of tetrahydro-quino[8,7-b][1,10] 
phenanthroline 280.[175] 
 
An entirely different route to the core system is illustrated in 
Scheme 93 which shows one example from six detailed.[176] 
Wittig reaction between the 2-bromoquinoline triphenylphos-
phonium salt 281 and 2-bromopyridine-3-carbaldehyde 
produced the cis alkene 282 which was cyclized to 283 by 




Scheme 93. An alternative route for the construction of a pyrido[3,2-
c]acridine 283.[176] 
 
A route in which one of the pyridine rings of 285 was formed 
at a late stage started from 9-methylacridine (Scheme 94). 4-
Nitration, reduction and then the amine was transformed into 
the cyclization precursor 284 by reaction with Meldrum’s acid 
and trimethoxymethane. Thermolysis of 284 produced the 






tetracyclic system 285 – an example of a standard route to 4-
quinolones.[177] A comparable ring construction was even 
possible after prior construction of an extra five-membered 
lactam, giving product 286, the work being relevant to the 
plakinidine alkaloids.[178] 
 
Scheme 94. Synthesis of a pyrido[3,2-c]acridone 285.[177] 
A copper-catalysed amination and a Friedel–Crafts cyclisation 
figured in the preparation of acid 287 and its conversion into 
the pyridoacridone 288 (Scheme 95).[148] An analogous 
sequence using 1-bromonaphthalene-2-carboxylic acid, 
instead of 2-bromobenzoic, led to 289.[149]  
 
Scheme 95. Conversion of 8-aminoquinoline into a pyrido[3,2-
c]acridone 288.[148] 
 
Moving to other methods for the construction of quinacridines 
(an extra benzene ring) the ortho-phenylene diamine 
derivative 290 was made by Buchwald-Hartwig double 
amination of an ortho-dibromobenzene with methyl 
anthranilate and the two pyridone rings in 291 made by a 
double Friedel–Crafts process (Scheme 96).[138] Reduction of 





Scheme 96. Double acylative cyclisation to produce a 
dibenzo[b,j][1,10]phenanthroline-dione 291.[138] 
 
In studies of rhodium-catalysed reactions of pyridine N-oxides, 
a couple of examples produced extended pyrido[2,3-




Scheme 97. Reaction of 2,2'-diquinoline N-oxide 292 with an 
acetylene.[179] 
 
The quinone-triflate 294 was aminated by a Buchwald-Hartwig 
cross-coupling with 8-aminoquinoline and the product 295 
closed to the heptacyclic compound 296 under strongly acidic 




Scheme 98. A one-off route to a 9H-anthra[1,9-bc][1,10] 
phenanthrolinone 296.[180] 
 
The extended ligand 298 (Scheme 99), synthesised as shown 
in Scheme 99 starting from 297, was used to produce a bis-
Pt(II) dimer 299 with an extended -face contact area, which 





Scheme 99. The construction of a polycyclic system 298 and its 
platinum complex 299.[181] 
 
Naphtho[2,1-b][1,10]phenanthrolines 303, termed NAPs, 
were synthesized as shown in Scheme 100. In particular, 
NAP-3 (Ar = 4-bromophenyl) was shown to be a dual 
colorimetric and ratiometric fluorescent probe for selective and 






‘direct’ visualization of labile iron(III) pools in the multicellular 
organism, Caenorhabditis elegans.[182] The 2-pyrone 300 was 
prepared by a standard route then reacted with ketone 301 




Scheme 100. Synthesis of naphtho[2,1-b][1,10]phenanthrolines 
303.[182] 
 
Of the heteroleptic copper complexes made from various 
ligands, that with 5,8-diphenyl-6,7-dihydrodibenzo [b,j][1,10] 
phenanthroline 304 was the best photosensitizer in a 
photocatalytic Cu-Fe water reduction system.[183] Compound 
304 was made from cyclohexane-1,2-dione and two 




Scheme 101. Synthesis of quino[8,7-b][1,10]phenanthroline 304.[183] 
 
The conversion of pyridine (or quinoline) 2- or 4-methyl groups 
into enamines (cf. Scheme 18) can also be used, by 
subsequent oxidation, as a means for conversion into 
aldehyde groups. Thus, pentacycle 305 was reacted with 
Bredereck's reagent (tert-butoxybis(dimethylamino)methane) 
giving 306, then oxidized to dialdehyde 307 (Scheme 102).[184] 
This work also showed preferential reaction of a pyridine 4-
methyl in the presence of a 2-methyl.  
 
Scheme 102. Conversion of quinoline methyl into aldehyde.[184]  
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